Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.
1 report, 1 independent
Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Biogen
American multinational biotechnology company
Nothing else this week.